Mednet takes pride in receiving a high recognition for working with Janssen to facilitate the Maintaining Adherence Programme (MAP), winning the inVentiv Health Communications Award for Excellence in Healthcare Collaboration and Partnerships and the KnowledgePoint360 Special Award for Innovation.
These Pharmaceutical Market Excellence Awards (PMEAs) recognise and encourage excellence and best marketing/business practice in the pharmaceutical and life science industries. PMEA reflects the new, intelligent and creative ways to bring about improvements in healthcare for patients and value for Healthcare Providers and payers in local, European and international healthcare markets. It is specifically designed to recognise and commend excellence, best practice and innovation.
The Maintaining Adherence Programme works on an innovative model of disease management with a potential to significantly improve the pathway for people with schizophrenia, bipolar and affective disorders. To date, MAP has delivered: outstanding patient, carer and staff experience/satisfaction results, considerable reduction in hospital admissions and significant improvements in efficiency/cost savings – fulfilling the QIPP agenda.
Mednet believes that winning awards in these categories act as a massive boost for the company to continue the hard work through innovation and marks a great sign of bright future prospects to meet the expectations of our clients to serve the healthcare industry in Europe and beyond.